Near-cure in Patients with Gadolinium Deposition Disease Undergoing Intravenous DTPA Chelation

Overview

Journal Front Toxicol

Date 2024 Aug 9

PMID 39118832

Authors

Richard C Semelka

Miguel Ramalho

Affiliations

Soon will be listed here.

Abstract

Purpose: To demonstrate and evaluate factors contributing to near-cures in patients with Gadolinium Deposition Disease (GDD) undergoing intravenous (IV) DTPA chelation.

Methods: Patients who had undergone or are currently undergoing DTPA chelation for GDD were included in this report based on their medical records that showed their perceived improvement was at least 80% back to normal. A survey was developed that included factors commonly reported by patients treated in one clinic to determine if these 'near-cured' (pre-MRI baseline health) individuals possessed certain factors and lacked others. The anonymized survey was emailed to these individuals by the principal treating physician, the only investigator not blinded to the subjects. This report describes clinical documentation of patient status and their underlying factors in individuals treated by the primary author, and no research was performed. The survey was sent to sixteen individuals; Fourteen patients completed it (10 females; 41.1 ± 11.2 y/o).

Results: The most common factor was the administration of ≤5 lifetime doses of a Gadolinium-Based Contrast Agents (GBCA) (12/14). Unconfounded agents triggering GDD were seen in nine subjects. Most subjects (12/14) initiated chelation in the first year after the causative GBCA, and most (11/14) underwent ≤10 chelations with DTPA. Good healthcare status prior to MRI was observed in 5 subjects. The majority (11/14) described their immune status as strong. Severe physical disability prior to chelation was seen in 1.

Conclusion: Subjects with GDD can experience near-cure with IV DTPA chelation. Factors surveyed that predict near-cure include the start of chelation in the first year, few GBCA administrations, and good health status before MRI with GBCA injection. Nonetheless, a few patients with predictors of less successful outcomes still experienced near-cure.

References

. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009; 107(6):403-5. View

Harvey H, Gowda V, Cheng G . Gadolinium Deposition Disease: A New Risk Management Threat. J Am Coll Radiol. 2019; 17(4):546-550. DOI: 10.1016/j.jacr.2019.11.009. View

Chodankar D . Introduction to real-world evidence studies. Perspect Clin Res. 2021; 12(3):171-174. PMC: 8323556. DOI: 10.4103/picr.picr_62_21. View

Maecker H, Siebert J, Rosenberg-Hasson Y, Koran L, Ramalho M, Semelka R . Acute Chelation Therapy-Associated Changes in Urine Gadolinium, Self-reported Flare Severity, and Serum Cytokines in Gadolinium Deposition Disease. Invest Radiol. 2021; 56(6):374-384. PMC: 8087628. DOI: 10.1097/RLI.0000000000000752. View

Denmark D, Ruhoy I, Wittmann B, Ashki H, Koran L . Altered Plasma Mitochondrial Metabolites in Persistently Symptomatic Individuals after a GBCA-Assisted MRI. Toxics. 2022; 10(2). PMC: 8879776. DOI: 10.3390/toxics10020056. View

Jackson D, MacIntyre T, Duarte-Miramontes V, DeAguero J, Escobar G, Wagner B . Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration. Fed Pract. 2022; 39(5):218-225. PMC: 9351733. DOI: 10.12788/fp.0258. View

Semelka R, Ramalho M, AlObaidy M, Ramalho J . Gadolinium in Humans: A Family of Disorders. AJR Am J Roentgenol. 2016; 207(2):229-33. DOI: 10.2214/AJR.15.15842. View

Maecker H, Wang W, Rosenberg-Hasson Y, Semelka R, Hickey J, Koran L . An initial investigation of serum cytokine levels in patients with gadolinium retention. Radiol Bras. 2020; 53(5):306-313. PMC: 7545733. DOI: 10.1590/0100-3984.2019.0075. View

Kim H, Lee S, Kim J . Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018; 33(34):e213. PMC: 6097073. DOI: 10.3346/jkms.2018.33.e213. View

10.

Semelka R, Ramalho J, Vakharia A, AlObaidy M, Burke L, Jay M . Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging. 2016; 34(10):1383-1390. DOI: 10.1016/j.mri.2016.07.016. View

11.

Burke L, Ramalho M, AlObaidy M, Chang E, Jay M, Semelka R . Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. Magn Reson Imaging. 2016; 34(8):1078-80. DOI: 10.1016/j.mri.2016.05.005. View

12.

Weinmann H, Brasch R, Press W, Wesbey G . Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol. 1984; 142(3):619-24. DOI: 10.2214/ajr.142.3.619. View

13.

McNamara C, Rahmani G . Gena Norris and gadolinium deposition disease-the impact of celebrity health disclosure on public awareness. Magn Reson Med. 2018; 80(4):1277-1278. DOI: 10.1002/mrm.27223. View

14.

Maecker H, Siebert J, Rosenberg-Hasson Y, Koran L, Ramalho M, Semelka R . Dynamic Serial Cytokine Measurements During Intravenous Ca-DTPA Chelation in Gadolinium Deposition Disease and Gadolinium Storage Condition: A Pilot Study. Invest Radiol. 2021; 57(1):71-76. PMC: 8664920. DOI: 10.1097/RLI.0000000000000803. View

15.

Layne K, Wood D, Dargan P . Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?. Clin Toxicol (Phila). 2019; 58(3):151-160. DOI: 10.1080/15563650.2019.1681442. View

16.

Varrassi G, Rekatsina M, Perrot S, Bouajina E, Paladini A, Coaccioli S . Is Fibromyalgia a Fashionable Diagnosis or a Medical Mystery?. Cureus. 2023; 15(9):e44852. PMC: 10560069. DOI: 10.7759/cureus.44852. View

17.

Semelka R, Ramalho M, Jay M, Hickey L, Hickey J . Intravenous Calcium-/Zinc-Diethylene Triamine Penta-Acetic Acid in Patients With Presumed Gadolinium Deposition Disease: A Preliminary Report on 25 Patients. Invest Radiol. 2018; 53(6):373-379. DOI: 10.1097/RLI.0000000000000453. View

18.

Semelka R, Ramalho M . Physicians with self-diagnosed gadolinium deposition disease: a case series. Radiol Bras. 2021; 54(4):238-242. PMC: 8354197. DOI: 10.1590/0100-3984.2020.0073. View

19.

Semelka R, Commander C, Jay M, Burke L, Ramalho M . Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. Invest Radiol. 2016; 51(10):661-5. DOI: 10.1097/RLI.0000000000000318. View

20.

Do C, DeAguero J, Brearley A, Trejo X, Howard T, Escobar G . Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution. Kidney360. 2021; 1(6):561-568. PMC: 8378745. DOI: 10.34067/kid.0000272019. View